secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001847903-23-000153
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q2 net loss $24.9M; cash $303.6M; SerpinPC registrational study dosing
-------------------------------------------------------------------------------

- Cash, equivalents and short-term investments $303.6M as of June 30; plus $15M ATM gross proceeds in Aug 2023; runway into 2026.
- Net loss $24.9M vs $64.7M YoY, including $24.1M tax benefit from valuation allowance release on deferred tax assets.
- R&D expenses $33.7M (Q2 2023) vs $53.7M (Q2 2022); G&A $13.3M vs $14.8M.
- SerpinPC registrational PRESent-2 study first subject dosed July 2023; FDA Fast Track designation received May 2023.
- LB206 (PD-L1xCD3 LockBody) nominated as second development candidate; ORX750 IND-enabling; preclinical data at World Sleep Congress Oct 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/0001847903-23-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/cnta-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer